PATH

UiPath (PATH) declined 1.43% to $13.06 in the latest session, underperforming the S&P 500's 1.11% loss. Despite a 6.89% monthly drop, the company maintains a Zacks Rank #2 (Buy) rating with positive earnings revisions.

Analysts project Q earnings of $0.19 per share (+18.75% YoY) and full-year revenue of $1.79 billion (+11.25% YoY). The stock trades at a Forward P/E of 16.7, below its industry average of 20.8.

UiPath (PATH) has gained 33% over six months, driven by expanding AI capabilities through its Maestro platform and improving profitability. Q2 revenues rose 13% to $410M with ARR climbing 12% to $1.94B. Trading at a forward P/E of 15.29 versus the industry average of 30.92, PATH appears undervalued. However, intensifying competition and uncertain enterprise spending pose risks to growth.

The article compares C3.ai and UiPath as investments in the agentic AI automation space. UiPath is recommended as the better buy due to its profitability, positive free cash flow, and consistent growth trajectory. C3.ai, while showing recent improvements like positive free cash flow and 73% quarter-over-quarter booking growth, remains unprofitable with substantial net losses and is still in early restructuring stages under CEO Thomas Siebel.